financetom
Business
financetom
/
Business
/
Phillips Edison Stock Is Up Wednesday After CEO Comments On $300M Deal Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Phillips Edison Stock Is Up Wednesday After CEO Comments On $300M Deal Activity
Jan 8, 2025 8:41 AM

Phillips Edison & Company, Inc. ( PECO ) shares are up after a slight dip in premarket trading on Wednesday following the announcement of its transaction activity for the quarter ending Dec. 31.

In his commentary, Phillips Edison ( PECO ) CEO Jeff Edison noted that the company completed over $300 million in acquisitions during 2024.

Edison highlighted that these acquisitions align with the company's long-term growth strategy. He remains focused on achieving an internal rate of return (IRR) of 9%.

In the fourth quarter of 2024, Phillips Edison ( PECO ) acquired four shopping centers: Shops at Cross Creek (24,188 sq. ft.) in Houston, Harpers Station (229,060 sq. ft.) in Cincinnati, Lakeland Village Center (83,542 sq. ft.) in Houston, and Northpark Plaza (52,192 sq. ft.) in Denver.

Also Read: US Stocks To Open Higher As Futures Advance: Christopher Wood Expects Trump’s Inflationary Policies To Hurt Market

The company plans to drive value by increasing occupancy and rent growth, with potential future development opportunities for outparcel retail spaces.

Notably, there were no dispositions during the quarter.

For the full year 2024, Phillips Edison ( PECO ) acquired 14 shopping centers and four land parcels for about $306 million, exceeding its acquisition target.

According to Benzinga Pro, Phillips Edison ( PECO ) stock has gained over 0.8% in the past year. Investors can gain exposure to the stock via Harbor Human Capital Factor US Small Cap ETF .

Price Action: Phillips Edison ( PECO ) shares are trading higher by 1.34% at last check Wednesday.

Read Next:

Yield Curve Normalization, Cheap Valuation, EPS Growth To Boost Banks In 2025: Truist Initiates Coverage On These 14 Regional Names

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CVS Health EPS Estimates Lowered Amid Rising Costs, Medical Loss Ratio Concerns, UBS Says
CVS Health EPS Estimates Lowered Amid Rising Costs, Medical Loss Ratio Concerns, UBS Says
Oct 22, 2024
04:22 PM EDT, 10/22/2024 (MT Newswires) -- CVS Health's ( CVS ) Q3, full-year 2024 and 2025 earnings per share forecasts have been lowered due to rising costs, elevated medical loss ratio and uncertainties surrounding its Medicare Advantage plans, UBS Securities said in a report emailed Tuesday. UBS discusses the uncertainty surrounding CVS's financial outlook, and how much of the...
Meta Platforms defeats shareholder lawsuit over child safety claims
Meta Platforms defeats shareholder lawsuit over child safety claims
Oct 22, 2024
(Reuters) - Meta Platforms ( META ) and Chief Executive Mark Zuckerberg won the dismissal of a lawsuit claiming they misled shareholders in Meta's proxy statement about their ability to ensure the safety of children who use Facebook and Instagram. In a decision on Tuesday, U.S. District Judge Charles Breyer in San Francisco said the plaintiff Matt Eisner failed to...
Texas Instruments Q3 EPS, Revenue Fall; Q4 Outlook Issued
Texas Instruments Q3 EPS, Revenue Fall; Q4 Outlook Issued
Oct 22, 2024
04:23 PM EDT, 10/22/2024 (MT Newswires) -- Texas Instruments ( TXN ) reported Q3 earnings late Tuesday of $1.47 per diluted share, down from $1.85 a year earlier. Analysts polled by Capital IQ expected $1.37. Revenue in the three months ended Sept. 30 fell to $4.15 billion from $4.53 billion a year earlier. Analysts surveyed by Capital IQ expected $4.12...
Vaxcyte Insider Sold Shares Worth $4,846,508, According to a Recent SEC Filing
Vaxcyte Insider Sold Shares Worth $4,846,508, According to a Recent SEC Filing
Oct 22, 2024
04:21 PM EDT, 10/22/2024 (MT Newswires) -- Andrew Guggenhime, President and CFO, on October 18, 2024, sold 42,000 shares in Vaxcyte ( PCVX ) for $4,846,508. Following the Form 4 filing with the SEC, Guggenhime has control over a total of 90,383 shares of the company, with 90,383 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1649094/000164909424000082/xslF345X05/wk-form4_1729627909.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved